RadioImmunoTargeting and Radionuclide Tumour Targeting

Our research group has its primary focus on the development and evaluation of new modalities for the improvement of radioimmunotargeting and targeted radionuclide tumour therapy to enhance the efficiency and applicability in the management of cancer.

We conduct translational research from the development of targeting molecules, via experimental studies in animal models, to clinical evaluation in humans.

The group has active members from the Department of Oncology at the Medical Faculty at Lund University, and the Department of Oncology at Skåne University Hospital.

• Division of Oncology at Department of Clinical Sciences